Calumet

CLMT · NASDAQ

$56.05+$0.51 (+0.92%)TodayMarket closed ·
Prev close $55.54

CLMT analyst rating

HoldConsensus of 4 analysts over the last 12 months. 25% rate it a buy.
  • Strong buy0
  • Buy1
  • Hold3
  • Underperform0
  • Sell0

12-month price target · 7 analysts

Average $56.61 (+1.0% upside)

Low
$40.40
Now
$56.05
High
$78.75

Upgrades and downgrades

The latest rating actions, newest first

CLMT analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Sep 2, 2026MaintainsBuy
UBSAug 25, 2026MaintainsNeutral
Goldman SachsAug 18, 2026MaintainsNeutral
TD CowenAug 12, 2026MaintainsHold
Goldman SachsJul 30, 2026MaintainsNeutral
HC Wainwright & Co.Mar 30, 2026MaintainsBuy
Goldman SachsMar 12, 2026MaintainsBuy
Goldman SachsJan 30, 2026MaintainsBuy
HC Wainwright & Co.Nov 10, 2025MaintainsBuy
Goldman SachsOct 22, 2025MaintainsBuy

The case for and against

Updated Jul 31, 2025

Bull case

Calumet Inc. is projected to see a significant increase in adjusted EBITDA, with expectations for growth from $151 million in 2024 to $482 million in 2025, and potentially reaching approximately $750 million by 2028, driven by high-margin renewable diesel (RD) and sustainable aviation fuel (SAF) sales. The company anticipates improvements in gross margins, forecasted to rise from 6% in 2024 to over 9% by 2026, supported by a strengthened balance sheet and substantial annual cost savings in debt service. Furthermore, the upcoming release of a $1.44 billion Department of Energy loan is expected to enhance production capabilities and create strategic opportunities for monetizing the Montana Renewables segment, allowing Calumet to capitalize on the growing demand for renewable fuels.

Bear case

Calumet Inc. has faced significant challenges with recent revenue streams, as evidenced by the Industry MarketIndex dropping from a historical average of $2.00/gallon to around $1.00/gallon, indicating a sustained period of depressed pricing in the market. The company reported a net loss of $40.7 million for the quarter, although this represented an improvement over the $49.1 million loss recorded in the previous quarter. These financial metrics, combined with the ongoing struggles in maintaining profitability, contribute to a negative outlook for Calumet's stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.